4-cyclohexyloxypyridine-2-carboxylic acid | 863507-75-9

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 英文名称: 4-cyclohexyloxypyridine-2-carboxylic acid
• 英文别名: 4-(Cyclohexyloxy)-2-pyridinecarboxylic acid
• CAS: 863507-75-9
• 化学式: C₁₂H₁₅NO₃
• 分子量: 221.256
• InChiKey: VHLJFCNRRVZINW-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.5
• 重原子数：
  16
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  59.4
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  4-cyclohexyloxypyridine-2-carboxylic acid 、 (S)-1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid (4-pentylphenyl)amide 在 1-(3-二甲基氨基丙基)-3-乙基碳二亚胺 作用下， 以 氯仿 为溶剂， 生成 (S)-2-(4-cyclohexyloxypyridine-2-carbonyl)-1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid(4-pentylphenyl)amide
  参考文献：
  名称：

  Discovery of 1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid diamides that increase CFTR mediated chloride transport

  摘要：

  A series of 1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid diamides that increase chloride transport in cells expressing mutant cystic fibrosis transmembrane conductance regulator (CFTR) protein has been identified from our compound library. Analoging efforts and the resulting structure-activity relationships uncovered are detailed. Compound potency was improved over 30-fold from the original lead, yielding several analogs with EC50 values below 10 nM in our cellular chloride transport assay. (c) 2005 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2005.02.041
• 作为产物：
  描述：

  4-Cyclohexyloxypyridine-2-carbonitrile 在 sodium hydroxide 、 水 、 盐酸 作用下， 以 乙醇 、 水 为溶剂， 反应 1.0h， 以89%的产率得到4-cyclohexyloxypyridine-2-carboxylic acid
  参考文献：
  名称：

  Tetrahydroisoquinoline derivatives for treating protein trafficking diseases

  摘要：

  本文披露了四氢异喹啉衍生物、包含它们的药物组合物以及治疗疾病的方法。所披露的化合物在治疗和预防由氯离子通道活性和/或蛋白质运输介导的疾病方面是有用的，包括但不限于与黏液纤毛清除受损有关的疾病，如囊性纤维化、支气管炎、肺气肿等。

  公开号：

  US20050176761A1

文献信息

• Tetrahydroisoquinoline derivatives for treating protein trafficking diseases
  申请人：Pregel J. Marko

  公开号：US20050176761A1

  公开（公告）日：2005-08-11

  Tetrhydroisoquinoline derivatives, pharmaceutical compositions comprising them and methods of treating disease are disclosed herein. The disclosed compounds are useful in the treatment and prevention of diseases mediated by chloride channel activity and/or protein trafficking, including, but not limited to, diseases associated with impaired mucociliary clearance such as cystic fibrosis, bronchitis, emphysema, and the like.

  本文披露了四氢异喹啉衍生物、包含它们的药物组合物以及治疗疾病的方法。所披露的化合物在治疗和预防由氯离子通道活性和/或蛋白质运输介导的疾病方面是有用的，包括但不限于与黏液纤毛清除受损有关的疾病，如囊性纤维化、支气管炎、肺气肿等。
• Discovery of 1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid diamides that increase CFTR mediated chloride transport
  作者：Bradford H. Hirth、Shuang Qiao、Lisa M. Cuff、Brian M. Cochran、Marko J. Pregel、Jill S. Gregory、Scott F. Sneddon、John L. Kane

  DOI：10.1016/j.bmcl.2005.02.041

  日期：2005.4

  A series of 1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid diamides that increase chloride transport in cells expressing mutant cystic fibrosis transmembrane conductance regulator (CFTR) protein has been identified from our compound library. Analoging efforts and the resulting structure-activity relationships uncovered are detailed. Compound potency was improved over 30-fold from the original lead, yielding several analogs with EC50 values below 10 nM in our cellular chloride transport assay. (c) 2005 Elsevier Ltd. All rights reserved.